Dr George Bakris Compares FIDELIO-DKD Renal Outcomes With Those of SGLT-2 Inhibitor Trials
Although their underlying mechanisms differ, finerenone reduces albuminuria to the same extent as SGLT-2 inhibitors, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.
Watch video Dr George Bakris Compares FIDELIO-DKD Renal Outcomes With Those of SGLT-2 Inhibitor Trials online, duration hours minute second in high quality that is uploaded to the channel AJMCtv 27 October 2020. Share the link to the video on social media so that your subscribers and friends will also watch this video. This video clip has been viewed 3,131 times and liked it 31 visitors.
